Johnson & Johnson $JNJ Holdings Lifted by Cornerstone Wealth Group LLC

Cornerstone Wealth Group LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 16.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 52,581 shares of the company’s stock after acquiring an additional 7,527 shares during the quarter. Cornerstone Wealth Group LLC’s holdings in Johnson & Johnson were worth $11,892,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Auto Owners Insurance Co boosted its position in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $6,924,523,000. Capital World Investors bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $2,005,942,000. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 41.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock valued at $2,571,124,000 after buying an additional 3,655,754 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $254.24 on Wednesday. The stock’s fifty day simple moving average is $231.79 and its 200 day simple moving average is $230.37. The stock has a market capitalization of $612.01 billion, a price-to-earnings ratio of 29.39, a PEG ratio of 2.53 and a beta of 0.26. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52-week low of $152.81 and a 52-week high of $259.90.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Morgan Stanley set a $283.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. HSBC increased their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Argus boosted their target price on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Raymond James Financial upped their target price on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Finally, Stifel Nicolaus lifted their price target on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $256.70.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson won a favorable jury outcome in a talc-related lawsuit, reducing some overhang from long-running legal risk tied to allegations that its products caused cancer. Article: Johnson & Johnson (JNJ) Beats Lawsuit Alleging that Talc caused Three Women’s Cancer
• Positive Sentiment: European regulators gave a positive CHMP opinion for expanded use of J&J’s Tecvayli in multiple myeloma, reinforcing confidence in the company’s oncology pipeline and future revenue growth. Article: J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
• Positive Sentiment: The stock hit a new 52-week high and was described as breaking out past a buy point, suggesting strong investor demand and continued momentum in the shares. Article: Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Positive Sentiment: Analyst and media coverage continues to highlight J&J as a dividend and healthcare leader, which can keep income-focused investors interested in the name. Article: Johnson & Johnson (NYSE:JNJ) Healthcare Rally Lifts Dividend Appeal
• Neutral Sentiment: Several articles focused on J&J’s recent rally and whether the stock still offers value after a strong run, which suggests investors are weighing upside potential against a rich valuation. Article: Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left
• Neutral Sentiment: The company was also noted as a trending stock and a passive-income favorite, reflecting sustained attention rather than a new fundamental catalyst. Article: Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: After six straight sessions of gains, J&J snapped its winning streak, indicating some short-term profit-taking as investors lock in recent gains. Article: Johnson & Johnson snaps six straight sessions of gains

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.